Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed thyroid carcinoma of
             follicular origin (including papillary and its respective variants).

          -  Patients should have tumors that are radiographically evident on PET, ultrasound, CT
             or MRI

          -  Age ≥ 18 years.

          -  ECOG performance status ≤ 2 (or Karnofsky ≥60%).

          -  Patients must have normal organ and bone marrow function as defined below:

               -  Absolute neutrophil count (ANC) > 1.5x10^9/L

               -  Hemoglobin ≥ 9 g/dL

               -  Platelets ≥ 100 x 10^9/L

               -  Albumin ≥ 2.5 g/dL

               -  Total bilirubin ≤ 1.5x institutional ULN

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2x
                  institutional ULN unless it is related to the primary disease

               -  Creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault
                  formula) ≥ 50 mL/min OR 24-hour urine creatinine clearance ≥ 50 mL/min

          -  Negative pregnancy test within 7 days prior to starting the study in premenopausal
             women. Women of non-childbearing potential may be included without pregnancy test if
             they are either surgically sterile or have been postmenopausal for ≥ 1 year.

          -  Fertile men and women must use an effective method of contraception during treatment
             and for at least 6 months after completion of treatment as directed by their
             physician. Effective methods of contraception are defined as those, which result in a
             low failure rate (i.e., less than 1% per year) when used consistently and correctly
             (for example implants, injectables, combined oral contraception or intra-uterine
             devices). At the discretion of the Investigator, acceptable methods of contraception
             may include total abstinence in cases where the lifestyle of the patient ensures
             compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal,
             postovulation methods] and withdrawal are not acceptable methods of contraception.)

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant, lactating, or breast feeding women.

          -  Patients unable to follow a low iodine diet or requiring medication with high content
             in iodide (amiodarone).

          -  Patients who received iodinated intravenous contrast as part of a radiographic
             procedure within 3 months of study registration. Those that have had iodinated
             intravenous contrast for CT imaging within this time frame may still be eligible if a
             urinary iodine analysis reveals that the excess iodine has been adequately cleared
             after the last intravenous contrast administration.

          -  Unwillingness or inability to comply with study procedures.